Blood-based MRD Test for Cancer Recurrence Can Generate Cost Savings in Colorectal Cancer Treatment, Finds Study in JAMA Health Forum
Circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) can reduce costs by up to 21% across health plan populations when half of eligible patients with stage II colorectal cancer are tested for treatment decisions SECAUCUS, N.J. and BALTIMORE, May 31, 2024 /PRNewswire/...
Circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) can reduce costs by up to 21% across health plan populations when half of eligible patients with stage II colorectal cancer are tested for treatment decisions SECAUCUS, N.J. and BALTIMORE, May 31, 2024 /PRNewswire/...
